Vukojevic J, Milavi M, Perovi D, Ili S, ili AZ, uran N, trbe S, Zorii Z, Filipi I, Brei P, Seiverth S, Sikiri P
Prescription options for refractory cases include lubiprostone (Amitiza), linaclotide (Linzess), plecanatide (Trulance), and prucalopride (Motegrity)
Tirzepatide: Adding a Second Metabolic Pathway Tirzepatide builds upon semaglutide by activating both: GLP-1 GIP (glucose-dependent insulinotropic polypeptide) Researchers believe activating both receptors may enhance metabolic regulation in some individuals
Your provider should baseline glutathione biomarkers and reassess every 812 weeks to ensure timing and dose remain appropriate
New aspects of immunological risk factors in the treatment of recurrent pregnancy loss
Insurance providers such as United Healthcare, Cigna, Blue Cross Blue Shield, and Aetna frequently provide coverage under certain conditions, particularly when accompanied by a prior authorization